policy+practice

Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent approval of aducanumab (Aduhelm) for dementia.

Health Evidence Network Synthesis Report 73

One that recently hit the market — winning Food and Drug Administration approval in June — is Novo Nordisk’s Wegovy, a higher-dose version of the company’s injectable diabetes drug, Ozempic.

The country has only been using the Pfizer/BioNTech COVID-19 vaccine so far.

The healthcare company faces legal actions from tens of thousands of plaintiffs, including women suffering from ovarian cancer and others with mesothelioma, alleging that its baby powder and other talc products contained asbestos and caused cancer.

In late March, under pressure to help other nations access COVID-19 vaccines, the Biden administration released 1.5 million AstraZeneca doses to Canada, and 2.5 million to Mexico.

Sales of the Swiss drug maker's major plaque psoriasis treatment Cosentyx in China quadrupled in the second quarter, despite its price being slashed by more than 60%.

The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.

The possible approval of aducanumab by Health Canada highlights a series of debates and concerns about how we approve new drugs.

Rep. Scott Peters once backed Democrats' price-control bill. Now critics say he's a "paid mercenary" for Big Pharma.

The Competition and Markets Authority (CMA) said the fine “sends a clear message” to the pharmaceutical industry that breaking the law will not be tolerated.

Competition watchdog found company’s ‘excessive and unfair’ prices cost NHS almost £30m extra over 10 years.

The only consistent aspect of drug pricing in the United States is that the breadth of its variations and fluctuations are inexplicable to the consumer.

Private equity firms Cinven and Hg have been fined by the U.K.’s competition watchdog after a pharmaceutical firm they once owned was found to have overcharged for crucial drugs.

Nearly two months after the Alzheimer's drug Aduhelm received conditional approval from the Food and Drug Administration, experts are still debating how, and whether, it should be used.